Cardio Diagnostics (NASDAQ:CDIO) Upgraded by Wall Street Zen to “Hold” Rating

Cardio Diagnostics (NASDAQ:CDIO) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cardio Diagnostics in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Cardio Diagnostics Stock Down 6.9%

Cardio Diagnostics stock opened at $2.29 on Friday. The stock has a 50-day simple moving average of $2.65 and a 200 day simple moving average of $3.28. The stock has a market capitalization of $4.19 million, a price-to-earnings ratio of -0.62 and a beta of 2.28. Cardio Diagnostics has a 12-month low of $0.97 and a 12-month high of $17.39.

Cardio Diagnostics (NASDAQ:CDIO) last issued its quarterly earnings data on Friday, March 13th. The company reported ($0.80) EPS for the quarter. Cardio Diagnostics had a negative return on equity of 71.75% and a negative net margin of 40,612.50%. As a group, sell-side analysts anticipate that Cardio Diagnostics will post -0.55 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cardio Diagnostics stock. Citadel Advisors LLC purchased a new position in shares of Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 19,520 shares of the company’s stock, valued at approximately $79,000. Citadel Advisors LLC owned about 1.07% of Cardio Diagnostics at the end of the most recent reporting period. Institutional investors own 8.06% of the company’s stock.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.